Ro-3306

Catalog No.S7747

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Cited by 4 Publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909

Sci Rep, 2017, 7:41950

PubMed: 28176818

3 Customer Reviews

HeLa cells were untreated or treated with either colcemid (10 μg/ml for 16 h), RO-3306 (9 μM for 16 h), or both colcemid and RO-3306, as indicated. Cells were then lysed, and proteins were detected by Western analysis.

J Cell Biol, 2015, 209(2): 221-34 . Ro-3306 purchased from Selleck.

A, Expression of IFIT3 in HeLa cells pretreated with 5 μM RO-3306 for 12 hours and then stimulated with type I IFN (1,000 units/ml) for 8 hours. The cells were collected and total RNA was extracted for the detection of IFIT3 mRNA. Results are the relative expression levels of IFIT3 mRNA normalized to endogenous GAPDH mRNA levels. B, Expression of IFI27 in HeLa cells measured in the same samples as in A.

Arthritis Rheumatol, 2016, 68(5):1222-32.. Ro-3306 purchased from Selleck.
AML cells were treated with AZ20 in the absence or presence of RO-3306 (RO) for 24 h. Cells were then subjected to annexin V-FITC/PI staining and flow cytometry analyses. Combined treatment was compared to AZ20 treatment alone using pair-wise two-sample t-test. ***Indicates p < 0.001.

Sci Rep, 2017, 7:41950. Ro-3306 purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human NCI-SNU-1 cell	NGjkU4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzNyOUWg{txO	MYLTRW5ITVJ?
human H460a cells	MkLDVJJwdGmoZYLheIlwdiCjc4PhfS=>		MkDyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKNE[wZUBk\WyuczygTWM2OD1zLkC0JO69VQ>?	NX;WNHVtOTd\|MEO0NlE>
human MDA435 cells	MlTVVJJwdGmoZYLheIlwdiCjc4PhfS=>		NYPPVFc6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGE1OzViY3XscJMtKEmFNUC9NU4yPCEQvF2=	NFfKenMyPzNyM{SyNS=>
human HCT116 cells	NVPrNI5LWHKxbHnm[ZJifGmxbjDhd5NigQ>?		MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczygTWM2OD1zLkG0JO69VQ>?	MVexO\|MxOzR{MR?=
human H4 cell	NHHxVYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NY[1TohtUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU5PzVizszN	NHT5T21USU6JRWK=
human PA-1 cell	MnfkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyOlU1KM7:TR?=	NFji[oZUSU6JRWK=
human T98G cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW\wfHlGUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjhzMjFOwG0>	M1;OPHNCVkeHUh?=
human SW1710 cell	M2fCUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1jNUmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OTRyODFOwG0>	NXLlOFc1W0GQR1XS
human U251 cell	NYHrSldMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWnJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[zO\|cyKM7:TR?=	MlvXV2FPT0WU
human ALL-PO cell	Ml\rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFvv[YlKdmirYnn0bY9vKG:oIHj1cYFvKEGOTD3QU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS57MEixN{DPxE1?	Ml;JV2FPT0WU
human RKO cells	NEjacnJRem:uaX\ldoF1cW:wIHHzd4F6		MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyxiSVO1NF0zKM7:TR?=	MWmxO\|MxOzR{MR?=
human SK-N-DZ cell	M1zvVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWHj[XFlUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMUi3OkDPxE1?	M1yzNXNCVkeHUh?=
human A4-Fuk cell	NFT1fnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlryTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA2PjB2IN88US=>	M3noUnNCVkeHUh?=
human SW480 cells	MWDQdo9tcW[ncnH0bY9vKGG\|c3H5		M{jZN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2e0PFAh[2WubIOsJGlEPTB;Mj6yJO69VQ>?	NYHxbGtqOTd\|MEO0NlE>
human 639-V cell	NIf6Vm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1LKN2lvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI4PTN5IN88US=>	MUnTRW5ITVJ?
human Hs-578-T cell	M1jaVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGh{NTV5OD3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzd7OTFOwG0>	NF;kU2FUSU6JRWK=
human UM-UC-3 cell	MmH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVIvPzN7M{[g{txO	MXLTRW5ITVJ?
human BPH-1 cell	NWrvdI5uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlXiTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVc1PTVizszN	NH3oNppUSU6JRWK=
human 5637 cell	MofCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF7UVFRKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA5PTN{IN88US=>	NUm0OWtDW0GQR1XS
human 8-MG-BA cell	M4rISGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mm\tTY5pcWKrdHnvckBw\iCqdX3hckA5NU2JLVLBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0{NjF2MES5JO69VQ>?	NUK1eppmW0GQR1XS
human HCT116 cells	MmDnR5l1d3SxeHnjxsBie3OjeR?=	NWDDdJIxPSCmYYnz	MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JG1VWyCjc4Phfg+9lCCLQ{WwQVMvOiEQvF2=	MUOyNlMzPjF4OB?=
human LB1047-RCC cell	NI\tZZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ\|NUCxJO69VQ>?	NEfLVY5USU6JRWK=
human KOSC-2 cell	MonnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVy5e2JJUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjR2Nk[2NkDPxE1?	MlLLV2FPT0WU
human COR-L88 cell	MonSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ4PTh\|IN88US=>	MWHTRW5ITVJ?
human PSN1 cell	NE\6SItIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml;GTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xNFgxPSEQvF2=	MUHTRW5ITVJ?
human LXF-289 cell	MlfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlIyPzZizszN	M3PN[nNCVkeHUh?=
human MN-60 cell	NUPzdnBjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2PQdmlvcGmkaYTpc44hd2ZiaIXtZY4hVU5vNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM4PjJ\|IN88US=>	NFnXZnRUSU6JRWK=
human NEC8 cell	MlX1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1;WO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFcxPzZizszN	M3POcnNCVkeHUh?=
human SJSA1 cells	M3Ptd3Bzd2yrZnXyZZRqd25iYYPzZZk>		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOMU1GxJINmdGy\|LDDJR\|UxRTRwNUWg{txO	MU[xO\|MxOzR{MR?=
human NCI-H2405 cell	NFzxO25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4fX[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC55NES5N{DPxE1?	MoTMV2FPT0WU
human YH-13 cell	M3jicmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUfBfIJXUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzV5N{[g{txO	NYTZPVFyW0GQR1XS
human SK-MEL-2 cell	NVjF[nBbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVXVOXBXUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwMEm2N\|Ih\|pyv	MVLTRW5ITVJ?
human NB13 cell	NXi3dHFuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGPNd\|FKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlMzPzh4IN88US=>	MYLTRW5ITVJ?
human GAMG cell	NW\xSYZiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4n6TWlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|cyPSEQvF2=	MkW5V2FPT0WU
human NCI-H1792 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnuxTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR5OUW0JO69VQ>?	M3LLSHNCVkeHUh?=
human KP-4 cell	MnXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[5PFI{KM7:TR?=	M4LlfnNCVkeHUh?=
human HGC-27 cell	M1;LOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHznRVJKdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzNyN{eg{txO	M3XEXXNCVkeHUh?=
human GCT cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVLNXYF3UW6qaXLpeIlwdiCxZjDoeY1idiCJQ2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg2OTJzIN88US=>	MVrTRW5ITVJ?
human PFSK-1 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXewZ2N2UW6qaXLpeIlwdiCxZjDoeY1idiCSRmPLMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh4MU[4JO69VQ>?	Mn3uV2FPT0WU
human A172 cell	M1PRe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkmwO\|kh\|ryP	NV6yZohqW0GQR1XS
human HO-1-N-1 cell	NGrxT\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MornTY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTV2MkWg{txO	NUTZNmx7W0GQR1XS
human HN cell	M4jCXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3nvXWlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3NFk4KM7:TR?=	M1q0XXNCVkeHUh?=
human IST-MES1 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NY\nVmdjUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe1NlEh\|ryP	Mmn6V2FPT0WU
human TGW cell	MlexS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWjxbZhSUW6qaXLpeIlwdiCxZjDoeY1idiCWR2egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA2Pjh{IN88US=>	M{jRZnNCVkeHUh?=
human COR-L23 cell	NVL0W5pIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM4OzVizszN	M4PhenNCVkeHUh?=
human D-566MG cell	MknQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1PBe2lvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzh6N{Og{txO	NHHjXFFUSU6JRWK=
human SKG-IIIa cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkHpTY5pcWKrdHnvckBw\iCqdX3hckBUU0dvSVnJZUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQDV3N{Kg{txO	Mlv6V2FPT0WU
human NCI-H446 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1T5dGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OFYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjBzOEGg{txO	NGHaUI5USU6JRWK=
human KYSE-270 cell	NFvHclZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NITBSIJKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNlcxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yM{i3NkDPxE1?	M3[wfHNCVkeHUh?=
human CAL-39 cell	NH7FVW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4q5Z2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PTJ2IN88US=>	M3HVeXNCVkeHUh?=
human IST-SL1 cell	NFPpbGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ{OzR7IN88US=>	MmGwV2FPT0WU
human SF539 cell	NUXGPHV2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz61OVE6PyEQvF2=	M3nlU3NCVkeHUh?=
human TE-1 cell	NYK1cZRDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2ex[WlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFkxQTFizszN	M1fhV3NCVkeHUh?=
human NB10 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3jmcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPVg4PThizszN	MYfTRW5ITVJ?
human 8505C cell	MkHRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGDkdWVKdmirYnn0bY9vKG:oIHj1cYFvKDh3MEXDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{46QThzNzFOwG0>	MlHmV2FPT0WU
human DB cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC5yMUGzNUDPxE1?	M13TdHNCVkeHUh?=
human NCI-H28 cell	NEG3coVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVLlc5VyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC53OUi4OEDPxE1?	MVjTRW5ITVJ?
human LOXIMVI cell	NFnXO\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY{PzBzIN88US=>	Mnq5V2FPT0WU
human ME-180 cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1GNTF6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuPFA{QTVizszN	M3TnRnNCVkeHUh?=
human ES3 cell	M1vQSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGVUOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTlwMUK3PVQh\|ryP	NWHQT3V5W0GQR1XS
human SK-N-FI cell	MnH4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHu0OZZKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjRzNkm5JO69VQ>?	NHfacFFUSU6JRWK=
human NBsusSR cell	NGTWfY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTNXmU4UW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMkOxPEDPxE1?	MmLuV2FPT0WU
human MCF7 cell	NYnvd3RGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xPFQ6KM7:TR?=	MlnSV2FPT0WU
human A549 cell	M4fUOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkPxTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUGuNlA3KM7:TR?=	NHvuSFZUSU6JRWK=
human HuP-T4 cell	NYfm[3BFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYrJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGwMlQzPzFizszN	MnLsV2FPT0WU
human HSC-2 cell	NHf5OYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUGsO\|g1OiEQvF2=	MWDTRW5ITVJ?
human A253 cell	MoDQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmH4TY5pcWKrdHnvckBw\iCqdX3hckBCOjV\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUWuNlg{PCEQvF2=	M3r3S3NCVkeHUh?=
human HCT-116 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4S3b2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG4MlAxPDNizszN	NUjyUGh6W0GQR1XS
human HCT-116 cell	MnflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NILoTmJKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS54Nkig{txO	MWLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand CDK assay: The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
Cell Research:^[3]	+ Expand Cell lines: MDA-MB-231 cell line Concentrations: 20 μM Incubation Time: 72 h Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength. (Only for Reference)

Kinase Assay:^[1]

+ Expand

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

+ Expand

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 4 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 4 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)